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INTRODUCTION
Correctly classifying patients with diabetes 
with type 1 or type 2 is fundamental 
to ensuring they receive correct 
management.1–3 In clinical practice this 
can be challenging, with 7–15% patients 
misclassified in England, and large 
variations in practice.4–7
Historical lack of clear clinical 
guidelines for diabetes classification is 
likely to have contributed to this variation. 
International guidelines from the World 
Health Organization8 and the American 
Diabetes Association9 base classification on 
underlying aetiology, with type 1 described 
as a destruction of beta cells leading to 
absolute insulin deficiency. However, these 
guidelines do not provide clear criteria or 
classification pathways for clinical use.8,9 A 
pragmatic classification algorithm (Figure 1) 
was thus developed in 2010 by key diabetes 
stakeholders in the UK, and published by 
the Royal College of General Practitioners 
(RCGP) and (the previously existing) NHS 
Diabetes in their Coding, Classification and 
Diagnosis of Diabetes document.4 This uses 
age at diagnosis and time to commencing 
insulin treatment from diagnosis as its 
diagnostic criteria. The efficacy of this 
algorithm has not yet been tested on a large 
cohort of patients with diabetes. 
The fundamental difference between 
type 1 and type 2 diabetes is the rapid 
development of absolute insulin deficiency 
in type 1, forming the basis of their different 
treatment and management. Patients 
with type 1 require accurate insulin dose 
replacement;10,11 patients with type 2 
continue to produce substantial amounts 
of their own insulin, responding to non-
insulin therapy, or if insulin is needed 
good control can be achieved with non-
physiological insulin regimens.12,13 
Measuring endogenous insulin secretion 
(using C-peptide, a component of the 
insulin pro-hormone secreted in equimolar 
amounts to insulin) in longstanding 
diabetes may be a useful ‘gold standard’ 
marker of endogenous insulin production, 
confirming a diagnosis of type 1 versus 
type 2 diabetes. Development of the spot 
urine test urinary C-peptide creatinine 
ratio (UCPCR)14–17 has enabled practical 
testing in a community setting. UCPCR is 
well-correlated with mixed meal tolerance 




Differentiating between type 1 and type 2 
diabetes is fundamental to ensuring appropriate 
management of patients, but can be challenging, 
especially when treating with insulin. The 2010 UK 
Practical Classification Guidelines for Diabetes 
were developed to help make the differentiation.
Aim
To assess diagnostic accuracy of the UK 
guidelines against ‘gold standard’ definitions of 
type 1 and type 2 diabetes based on measured 
C-peptide levels.
Design and setting
In total, 601 adults with insulin-treated diabetes 
and diabetes duration ≥5 years were recruited in 
Devon, Northamptonshire, and Leicestershire. 
Method
Baseline information and home urine sample 
were collected. Urinary C-peptide creatinine 
ratio (UCPCR) measures endogenous insulin 
production. Gold standard type 1 diabetes 
was defined as continuous insulin treatment 
within 3 years of diagnosis and absolute insulin 
deficiency (UCPCR<0.2 nmol/mmol ≥5 years 
post-diagnosis); all others classed as having 
type 2 diabetes. Diagnostic performance of the 
clinical criteria was assessed and other criteria 
explored using receiver operating characteristic 
(ROC) curves.
Results
UK guidelines correctly classified 86% of 
participants. Most misclassifications occurred in 
patients classed as having type 1 diabetes who 
had significant endogenous insulin levels (57 out 
of 601; 9%); most in those diagnosed ≥35 years 
and treated with insulin from diagnosis, where 37 
out of 66 (56%) were misclassified. Time to insulin 
and age at diagnosis performed best in predicting 
long-term endogenous insulin production 
(ROC AUC = 0.904 and 0.871); BMI was a less 
strong predictor of diabetes type (AUC = 0.824). 
Conclusion
Current UK guidelines provide a pragmatic 
clinical approach to classification reflecting long-
term endogenous insulin production; caution is 
needed in older patients commencing insulin 
from diagnosis, where misclassification rates are 
increased.
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of 0.2 nmol/mmol gives a sensitivity and 
specificity of 100% and >95% for detecting 
severe insulin deficiency16,17 as defined 
by the gold-standard mixed meal test 
90-minute C-peptide level of 200 pmol/L.18
Therefore, this study aimed to determine 
the reliability of the 2010 UK Practical 
Classification Guidelines4 to correctly 
classify diabetes in a large cohort of insulin-
treated participants against ‘gold-standard’ 
classification based on measurement 
of C-peptide, in those with diabetes of 
≥5 years’ duration. Although UCPCR can 
be used at any stage in diabetes to confirm 
endogenous insulin levels, in the current 
study ≥5 years’ duration was chosen to 
avoid misclassifying people with early type 1 




Adults with insulin-treated diabetes 
centred in/around three UK centres (Exeter, 
Northampton and Leicester) were sent 
letters before attending routine diabetes 
appointments or retinal screening (in 
primary care, both urban and rural, and 
secondary care). Those expressing an 
interest in participating either by returning 
an expression of interest form in advance, or 
when arriving for their routine appointment, 
were formally consented on the same day, 
and provided the research team with data 
on:
• age at diagnosis; 
• weight at diagnosis; 
• current age;
• weight and height;
• treatment; 
• time to insulin from diagnosis; and
• ethnicity.
Body mass index (BMI) at diagnosis and 
recruitment were calculated where possible; 
weight at diagnosis for those diagnosed as 
children converted to the adult equivalent 
using the UK Child Growth Reference 
Standards.19 Participants were also given a 
boric acid-containing urine specimen pot 
and padded stamped addressed envelope. 
They were asked to collect a urine sample 
for UCPCR14 2 hours after their largest 
meal of a day, and post the next morning 
(within 24 hours) for analysis in the Exeter 
biochemistry laboratory. UCPCR is stable in 
boric acid at room temperature for at least 
3 days.14 There was no financial incentive for 
participating.
Classification of diabetes 
Participants were classified as having type 1 
or type 2 diabetes using the UK guidelines,4 
(Figure 1). The authors developed ‘gold-
standard’ criteria: type 1 diabetes: 
continuous insulin treatment within the first 
3 years of diagnosis and absolute insulin 
deficiency (UCPCR <0.2 nmol/ mmol 
≥5 years post-diagnosis);16 type 2 
diabetes: UCPCR >0.2 nmol/mmol, or 
UCPCR <0.2 nmol/mmol but not treated 
with insulin for first 3 years after diagnosis. 
Statistical analysis 
Proportions of patients correctly classified 
by the UK guidelines according to the 
‘gold standard’ C-peptide-based definition 
were calculated, and differences in clinical 
characteristics between those correctly and 
incorrectly categorised were explored using 
the Mann-Whitney test. 
Diagnostic performance of continuous 
variables (age at diagnosis, time to insulin, 
How this fits in
Correct classification as type 1 or type 2 
diabetes is fundamental to appropriate 
diabetes management. The UK Practical 
Classification Guidelines for Diabetes 
published by the Royal College of General 
Practitioners and (the previously existing)
NHS Diabetes are pragmatically based on 
age at diagnosis and time from diagnosis 
to commencing insulin treatment. 
This the first study testing the UK 
classification guidelines in a large cohort 
of insulin-treated patients against a gold 
standard classification of diabetes subtype 
based on presence or absence of retained 
endogenous insulin secretion (measured 
using C-peptide) >5 years post-diagnosis.
The UK classification criteria correctly 
classified 86% of patients, with age at 
diagnosis and time to insulin being the 




Diagnosis <35 yearsa AND continual insulin
treatment within 6 months of diagnosis
OR
Diagnosis ≥35 yearsa AND continual insulin
treatment from diagnosis
aIn high-risk ethnicities a cut-off of 30 years should be used.
Type 2
Diagnosis <35 yearsa AND not on continual
insulin treatment within 6 months of diagnosis
OR
Diagnosis ≥35 yearsa AND not on continual
insulin treatment from diagnosis
Figure 1. UK Practical Classification Guidelines for 
Diabetes (extract showing algorithm of classification 
guidelines for type 1 and type 2 diabetes).4
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BMI at diagnosis and recruitment) was 
assessed using receiver operating 
characteristic (ROC) curves. Optimal cut-
offs for these variables (with maximum 
specificity and sensitivity for discrimination) 
were calculated, and this study explored 
whether use of these optimal cut-offs led 
to improvements in classification over 
and above the RCGP algorithm using net 
reclassification improvement.20 
Detailed subgroup analysis could not be 
carried out on the Asian patients due to 
small numbers. Analysis was carried out 
on Stata (version 13.1) and R (version 3.1.2). 
RESULTS
In total, 601 white European and 30 
Asian patients who had had diabetes 
for ≥5 years responded. Table 1 shows 
the characteristics of participants per 
classification 
UK guidelines versus gold standard
The UK clinical classification criteria were 
compared with the gold standard C-peptide 
based criteria for defining type 1 and 
type 2 diabetes in the cohort of 601 white 
European patients. In total, 514 (86%, 95% 
confidence interval [CI] = 83 to 88) patients 
overall were correctly classified by the UK 
guidelines when compared with the gold 
standard criteria. 
Figure 2 shows 163 out of 193 patients 
(84%, 95% CI = 79 to 89) were correctly 
classified with type 1 diabetes, and 351 out 
of 408 (86%, 95% CI = 82 to 89) with type 2 
diabetes. The extent of the agreement 
between the classifications of diabetes type 
using the UK guidelines compared with the 
gold standard is evident in Figure 3. 
In the Asian group, the criteria (taking note 
of the age cut-off of 30 years for high-risk 
ethnicities) performed less well, classifying 
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Table 1. Participant characteristics
  Gold standard UK guidelines Gold standard UK guidelines 
 Overall type 1 diabetes type 1 diabetes type 2 diabetes type 2 diabetes
Age at recruitment,  64 54 53 68 68 
median years  (53–73) (41–64) (41–64) (60–74) (61–75) 
(IQR)
Sex, % male 58.2 48.7 52.7 62.8 61.4
BMI at 28.7 26.5 26.8 29.7 30 
recruitment,  (25.3–33.3) (23.1–29.3) (23.8–29.7) (26.6–34.5) (26.6–34.1) 
median (IQR)
Age at diagnosis, 45 24 25 50 50 
median years  (30–56) (12–36) (13–39) (42–59) (43–58) 
(IQR)
BMI at 27 21.8 22.9 28.4 28.3 
diagnosis,  (23.9–32.0) (19.8–26.3) (20.0–27.6) (25.4–32.9) (25.2–33.6) 
median (IQR)
Latest HbA1c,  8.0 8.1 8.0 7.9 7.9 
% (IQR) (7.3–8.8) (7.4–8.9) (7.3–8.9) (7.2–8.8) (7.3–8.8)
Insulin, 0.64 0.61 0.61 0.65 0.64 
IU/kg/24 hours (0.44–0.90) (0.50–0.84) (0.49–0.88) (0.42–0.93) (0.43–0.92) 
(IQR)
UCPCR, 0.6 0.019 0.019 1.19 1.1 
nmmol/mmol,  (0.03–1.60) (0.019–0.03) (0.019–0.22) (0.59–2.25) (0.4–2.1) 
median (IQR)     
BMI = body mass index. IQR = interquartile range. UCPCR = urinary C-peptide creatinine ratio.
Figure 2. Classification of type of diabetes according 
to UK guidelines’ clinical criteria compared to ‘gold 
standard’ C-peptide-based criteria.
3  British Journal of General Practice, Online First 2016
for comparison with white Europeans) (data 
not shown). Three out of four (75%) were 
correctly classified with type 1 diabetes, and 
18 out of 26 (69%) with type 2 diabetes.
Misclassifications
Of patients misclassified by the UK 
guidelines’ clinical criteria in comparison 
with the gold standard (n = 87), most 
(n = 57, 66%, Figure 2) were misclassified as 
having type 1 diabetes and were producing 
substantial endogenous insulin ≥5 years 
post diagnosis (data not shown). Thirty out 
of 87 patients (34%) were misclassified 
as having type 2 diabetes (Figure 2); these 
individuals were severely insulin deficient 
and had started insulin treatment within 
3 years of diagnosis. 
The majority of misclassifications 
(eight out of nine) in the Asian group were 
also cases in which the UK guidelines’ 
criteria suggested type 1 diabetes (using 
the UK guidelines’ age cut-off of 30 years 
for high-risk ethnicities) but the patients 
were still producing their own insulin 
(data not shown). Most patients who were 
misclassified as having type 1 diabetes 
were diagnosed aged ≥35 years, and were 
given insulin immediately. According to UK 
guidelines, 66 patients had type 1 diabetes 
by these criteria, however 37 of these (56%) 
had a UCPCR of >0.2 nmol/mmol and 
so, by gold standard criteria, had type 2 
diabetes (Figure 2). 
Those misclassified as having 
type 1 diabetes were older than those 
correctly classified (median age 44 years 
[interquartile range {IQR} 30–59 years] 
versus 20 years [IQR 11–30 years], P <0.001) 
and had a higher BMI at diagnosis (26.4 kg/
m2 [IQR 23–30.3 kg/m2] versus 21.8 kg/m2 
[IQR 18.9–25.4kg/m2], P = 0.002) (data not 
shown). 
In contrast, those who were insulin 
deficient but were incorrectly classified by 
UK guidelines as having type 2 diabetes 
commenced insulin treatment more 
quickly than those correctly classified as 
having type 2 diabetes (time to insulin from 
diagnosis 12 months [IQR 2–18 months]) 
versus 84 months [IQR 42–138 months], 
P <0.001), had lower BMI (22.5 kg/m2 
[IQR 21.1–26.3 kg/ m2] versus 28.1 kg/
m2 [IQR 25.4–33.3 kg/m2], P <0.001), 
and were younger at diagnosis (44 years 
[IQR 35–56 years] versus 51 years 
[IQR 43–59 years], P= 0.014).
Optimal clinical criteria 
ROC curves were used to examine the 
discriminative ability of key clinical 
criteria: time to insulin, age at diagnosis, 
BMI at diagnosis, and BMI at recruitment 
(Figure 4). They were also used to identify 
the best cut-offs for classification based on 
the ‘gold standard’ criteria. An area under 
the curve (AUC) equal to 1 represents the 
perfect discrimination between types of 
diabetes, and an AUC of >0.8 is generally 
deemed clinically useful.
The most discriminatory individual 
characteristic was months from 
diagnosis to insulin treatment (AUC 0.904, 
95% CI = 0.88 to 0.93), with the optimal cut-
off at 12 months. In total, 91.5% patients 
were correctly classified as having type 1 
diabetes and 82.1% were correctly classified 
as having type 2 diabetes (data not shown). 
Age at diagnosis was also a useful 
discriminator between type 1 and type 2 
diabetes (AUC 0.871, 95% CI = 0.84 to 0.90), 
with the optimal cut-off being ≤39 years 
for type 1 diabetes. This correctly classified 
81.9% of patients with type 1 and 84.3% of 
those with type 2 diabetes (data not shown).
BMI at diagnosis gave an AUC of 0.824 
(95% CI = 0.77 to 0.87; data were available 
in 359 of 601 [59.7%] patients only), with the 
optimal cut-off being ≤23.1 kg/m2. However, 

















AD <35 & TTI<6m
Type 1 Type 2
AD <35 & TTI≥6mAD ≥35 & TTI = 0m AD ≥35 & TTI>0m
Figure 3. Proportion of patients classified as having 
type 1 or type 2 diabetes according to the UK 
guidelines. aAccording to C-peptide-derived gold 
standard definition. AD = age at diagnosis. TTI = time 
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Figure 4. Receiver operating characteristic curve for 
discriminating between type 1 and type 2 diabetes 
(Based on the gold standard definition).
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those with type 2 diabetes, it only classified 
65.7% of patients with type 1 correctly .
BMI at recruitment was even less 
discriminatory, with an AUC of 0.72 
(95% CI = 0.67 to 0.76) and an optimal cut-
off of 28.0 kg/m2; this correctly classified 
66.8% of people with type 2 diabetes, and 
61.8% of people with type 1 diabetes.
Modifying the guidelines’ clinical criteria 
The UK guidelines use age at diagnosis and 
time to insulin as the classification criteria 
to differentiate between type 1 and type 2 
diabetes. On the basis of the ROC curve 
data, the optimal cut-offs for time to insulin 
(12 months), age at diagnosis (39 years), BMI 
at diagnosis (23.1 kg/m2), and recruitment 
(28.0 kg/m2) were incorporated into modified 
criteria in various combinations to see 
whether they improved diagnostic accuracy. 
Aiming for a sensitivity and specificity of 
>80% (equivalent to an ROC AUC of >0.8), 
none were superior to the UK guidelines as 
improvements in sensitivity led to greater 
decreases in specificity and vice versa. 
The best-performing alternative was the 
combination of an age cut-off of 39 years 
and time to insulin of 12 months; this 
improved the correct classification of those 
with type 2 diabetes to 94%, but reduced 
to 78.3% those correctly classified with 
type 1 diabetes. In general, adding BMI at 
diagnosis or time of recruitment improved 
the proportion of those with type 2 diabetes 
that were correctly classified, but markedly 
reduced the proportion correctly classified 
with type 1 diabetes.
DISCUSSION
Summary
The study results show that the UK guidelines 
are an accurate method of predicting long-
term endogenous insulin production and 
perform well in correctly classifying patients 
with insulin-treated diabetes based on the 
development of absolute insulin deficiency 
using endogenous insulin levels and time 
to insulin from diagnosis. This supports the 
guidelines’ use as a beneficial, pragmatic 
way of classifying patients. When all 
patients with diabetes are considered, the 
authors hypothesise that the performance 
of the UK guidelines will be even better 
because the vast majority of patients who 
are not treated with insulin will be correctly 
classified as having type 2 diabetes.
Patients diagnosed at an older age 
(≥35 years) in whom insulin treatment 
commenced at diagnosis are at the highest 
risk of being misclassified when using the 
UK guidelines.
In clinical practice, emphasis is often 
placed on BMI to help differentiate between 
type 1 and type 2 diabetes but the study 
findings presented here indicate that, 
among patients treated with insulin, time 
to insulin and age at diagnosis are better 
predictors of diabetes subtype than BMI. 
Median BMI at diagnosis of those with type 1 
diabetes by the gold standard criteria was 
lower than in those with type 2 diabetes: 
21.8 kg/m2 versus 28.1 kg/m2 (P <0.001 but 
the interquartile ranges overlapped (19.8–
26.3 kg/m2 and 25.4–32.9 kg/m2). By the 
time of recruitment (that is, ≥5 years from 
diagnosis), the difference in BMI between 
those with type 1 and type 2 diabetes 
was smaller (26.5 kg/m2 [23.1–29.3 kg/
m2] versus 29.7 kg/m2 [26.6–34.5 kg/m2]) 
although still significant (P <0.001), and the 
ROC AUC was low, highlighting the reduced 
discriminative ability of this as a clinical 
marker to differentiate between type 1 and 
2 diabetes once the patient was receiving 
insulin.
Strengths and limitations 
This study comprised patients who had 
had diabetes for ≥5 years. If considering all 
patients with diabetes, the misclassification 
rate of 14% is likely to be much lower: 
patients who are treated with tablets or 
diet who were diagnosed ≥5 years ago are 
likely to have been correctly diagnosed with 
type 2 diabetes. In patients with a diabetes 
duration of <5 years, some patients with 
type 1 diabetes may be still producing insulin 
(the ‘honeymoon’ period) and not yet treated 
with insulin, although it is rare for patients 
with type 1 diabetes to be without insulin 
for prolonged periods. Due to recruitment 
locations and difficulty in recruiting Asian 
patients,21 the majority of the recruited 
patients were white European; only 30 Asian 
patients participated. Take-up rates in the 
white European population were high, and 
participants drawn from urban and rural 
populations, and thus the authors consider 
the results in this group are likely to be fairly 
representative for insulin-treated patients 
≥5 years from diagnosis. In comparison, the 
authors cannot comment on the reliability 
of the UK guideline criteria for populations 
in which the prevalence of diabetes is high; 
further work is needed in these groups. 
Limited data on BMI were available 
at diagnosis, due to a combination of 
participants not knowing their weight at 
diagnosis and/or missing details in GP 
records in patients having been diagnosed 
with diabetes ≥5 years ago. Improved 
recording of such details in those newly 
diagnosed with diabetes over the last few 
years means the authors consider this 
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information is likely to be more available in 
any future studies. 
The gold standard criteria used a 
UCPCR cut-off of 0.2 nmol/mmol, which 
has a sensitivity and specificity of 100% 
and >95% respectively to detect absolute 
insulin deficiency.16,17 It is the best gold 
standard available in this context, being 
practical for use in large numbers of adults 
living in the community. Insulin treatment 
has the potential to suppress endogenous 
insulin,22–24 but the findings presented 
here show that this rarely affects diabetes 
classification.24 In addition, it should be noted 
that the small possibility of an overdiagnosis 
of type 1 diabetes is a safer direction of error 
than the opposite.
Comparison with existing literature
Previous reports on the misclassification 
of diabetes4,6,25,26 were mainly based on 
contraindications in coding rather than 
on gold standard definitions of insulin 
deficiency.18,27,28 These reports have 
attempted to assess accuracy of recorded 
diagnosis on the basis of electronically 
recorded data. Although this may detect 
patients who are miscoded, for example as 
having type 1 diabetes but are not on insulin 
10 years postdiagnosis, it is less likely to 
detect patients who are misdiagnosed, 
for example in receiving insulin despite 
high endogenous insulin levels several 
years after diagnosis. The UK Practical 
Classification Guidelines for Diabetes4 use 
very simple clinically available information 
to classify patients from scratch, and the 
authors have assessed their accuracy 
using a gold-standard diagnosis based 
on endogenous insulin levels and time to 
insulin.
A recently published systematic review 
identified diagnostic accuracy studies in the 
literature, which compared clinical criteria 
with C-peptide cut-offs.7 Age at diagnosis, 
time to insulin, and BMI are the clinical 
characteristics most frequently used to 
classify type 1 and type 2 diabetes, but 
few studies have addressed clearly which 
are most strongly associated with long-
term C-peptide secretion.7 Where strength 
of association has been measured, time 
to insulin and age at diagnosis appear 
stronger than BMI. Again as found in the 
current study, combining time to insulin 
and age at diagnosis improved diagnostic 
accuracy, with BMI adding little.7 
Implications for research and practice
Correct classification of type 1 and type 2 
diabetes is important so the appropriate 
treatment and management guidelines are 
followed;3,29 this will relate to treatment, 
education (for example, about dose 
adjustment for normal eating for those with 
type 1), and the monitoring of complications, 
all of which are based on the presence or 
absence of endogenous insulin.
The clinical problem facing GPs and other 
health professionals is that classification 
can be tricky at the time of diagnosis and all 
guidelines — including the UK classification 
guidelines assessed in this study — rely 
on information that is only available 
further down the line (for example, time 
to insulin). The gold standard classification 
using UCPCR ≥5 years from diagnosis, 
by definition, cannot completely solve this 
conundrum: UCPCR of >0.2 nmol/mol 
within 5 years of diagnosis may represent 
someone with type 1 diabetes who is still in 
the ‘honeymoon’ phase, or someone with 
type 2 diabetes; a UCPCR of <0.2 nmol/
mmol within 5 years of diagnosis can 
diagnose type 1 diabetes however. 
Studies designed to improve classification 
at diagnosis, for example by using islet 
antibodies, are needed to address this 
problem. 
This study has shown that the UK 
guidelines based on time to insulin and age 
at diagnosis are accurate and pragmatic 
for classifying patients with type 1 or type 2 
diabetes. Time to insulin is subject to many 
influences — physician or patient factors, 
or guidelines for treatment in a particular 
area or patient population — but the high 
rate of correlation of diagnosis with the 
gold standard suggests overall timing 
of insulin initiation may be reasonably 
consistent. Clinically, where the type of 
diabetes is unclear, giving insulin from 
diagnosis is a rational decision to avoid 
the potential consequences of untreated 
type 1 diabetes, such as ketoacidosis. This 
study however demonstrates high rates 
of misclassification as type 1 diabetes in 
those diagnosed >35 years of age, and thus 
revisiting the diagnosis in these patients 
may be worthwhile. The authors suggest 
that, if there is diagnostic uncertainty, the 
diagnosis be reviewed, specialist advice 
sought, and further investigations (for 
example, C-peptide and islet autoantibodies) 
be considered.
It could be interesting to follow up 
those patients identified as misclassified, 
and those diagnosed with type 2 and 
still producing insulin beyond 5 years to 
ascertain whether some of them may be 
able to withdraw successfully from insulin.
The authors have concentrated on the 
two main types of diabetes, but recognise 
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that there are alternative subgroups such 
as genetic forms of diabetes. Although 
rare, these are also covered by the UK 
guidelines and have their own criteria for 
diagnosis.30
It is important that clinicians take into 
account other factors that may indicate 
these. The term ‘latent autoimmune 
diabetes in adults’ (LADA) is sometimes 
proposed for adults with islet autoantibodies 
who eventually (>12 years) become severely 
insulin deficient, but do not require insulin 
for at least the first 6 months.31–34 However, 
LADA is not included in international 
guidelines for classification/treatment.
 Finally, nothing was found to indicate 
that modification of the criteria used or 
the cut-offs proposed would improve 
their diagnostic performance. This study, 
like others such as that of Shields et al,7 
suggest that age of diagnosis is a better 
clinical predictor of type 1 diabetes than 
BMI, which is often used clinically to 
determine diabetes subtype when it is not 
clinically obvious; this supports the fact 
that more emphasis should be placed on 
age of diagnosis in uncertain cases. This 
is perhaps particularly relevant in a time 
when the BMI of the average population is 
increasing.35,36 
This study demonstrates that the UK 
Practical Classification Guidelines for 
Diabetes are an accurate means for 
differentiating between type 1 and type 2 
diabetes in most instances, with time to 
insulin and age at diagnosis being the most 
discriminatory clinical characteristics. As 
patients aged ≥35 years who were treated 
with insulin from diagnosis had the highest 
rate of misclassification (56% classed 
incorrectly as having type 1 diabetes), 
further investigation should be considered 
in this subgroup.
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